biote Corp. (BTMD) Financial Ratios
7 years of historical data (2019–2025) · Healthcare · Medical - Care Facilities
EV/EBITDA
↑
4.73
-6% vs avg
5yr avg: 5.05
30Y Low2.4·High8.1
P/FCF
↑
3.30
↓-19% vs avg
5yr avg: 4.09
30Y Low2.5·High5.5
P/B Ratio
N/A
—
5yr avg: 17.99
30Y Low18.0·High18.0
ROE
N/A
—
5yr avg: 790.8%
Debt/EBITDA
↑
2.80
+3% vs avg
5yr avg: 2.72
30Y Low1.0·High3.9
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
BTMD Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
biote Corp. trades at 3.1x earnings, 91% below its 5-year average of 33.0x, sitting at the 0th percentile of its historical range. Compared to the Healthcare sector median P/E of 22.1x, the stock trades at a discount of 86%. On a free-cash-flow basis, the stock trades at 3.3x P/FCF, 19% below the 5-year average of 4.1x.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Market Cap | $100M | $95M | $212M | $127M | $30M | $74M | — | — |
| Enterprise Value | $185M | $181M | $283M | $153M | $71M | $85M | — | — |
| P/E Ratio → | 3.05 | 3.51 | 67.10 | 38.00 | 23.31 | — | — | — |
| P/S Ratio | 0.52 | 0.50 | 1.07 | 0.69 | 0.18 | 0.53 | — | — |
| P/B Ratio | — | — | — | — | — | 17.99 | — | — |
| P/FCF | 3.30 | 3.16 | 5.46 | 5.25 | — | 2.48 | — | — |
| P/OCF | 2.83 | 2.71 | 4.68 | 4.72 | — | 2.20 | — | — |
P/E links to full P/E history page with 30-year chart
BTMD EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
biote Corp.'s enterprise value stands at 4.7x EBITDA, 6% below its 5-year average of 5.1x. The Healthcare sector median is 14.2x, placing the stock at a 67% discount on an enterprise-value basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 0.94 | 1.44 | 0.82 | 0.43 | 0.61 | — | — |
| EV / EBITDA | 4.73 | 4.62 | 8.05 | 5.19 | — | 2.36 | — | — |
| EV / EBIT | 5.22 | 5.10 | 23.58 | 3.95 | 12.37 | 2.45 | — | — |
| EV / FCF | — | 6.00 | 7.30 | 6.32 | — | 2.83 | — | — |
BTMD Profitability
Margins and return-on-capital ratios measuring operating efficiency
biote Corp. earns an operating margin of 18.5%. Operating margins have expanded from 15.5% to 18.5% over the past 3 years, signaling improving operational efficiency. ROIC of 1129.3% represents excellent returns on invested capital.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | 71.5% | 71.5% | 70.5% | 68.8% | 66.9% | 65.0% | 61.5% | 60.4% |
| Operating Margin | 18.5% | 18.5% | 16.0% | 15.5% | -36.8% | 24.8% | 27.3% | 21.4% |
| Net Profit Margin | 14.1% | 14.1% | 1.6% | 1.8% | -0.6% | 23.4% | 25.0% | 19.4% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| ROE | — | — | — | — | — | 790.8% | — | — |
| ROA | 23.5% | 23.5% | 2.3% | 2.5% | -1.2% | 75.1% | 103.3% | 89.1% |
| ROIC | 1129.3% | 1129.3% | — | — | — | 227.7% | 404.3% | 474.5% |
| ROCE | 53.3% | 53.3% | 31.0% | 25.4% | -93.5% | 119.4% | 203.4% | 226.7% |
BTMD Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
biote Corp. carries a Debt/EBITDA ratio of 2.8x, which is moderately leveraged (13% below the sector average of 3.2x). Net debt stands at $86M ($110M total debt minus $24M cash). Interest coverage of 3.2x is adequate, though a cyclical earnings downturn could tighten the margin of safety.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — | 9.05 | — | — |
| Debt / EBITDA | 2.80 | 2.80 | 3.15 | 3.90 | — | 1.04 | 1.29 | 1.93 |
| Net Debt / Equity | — | — | — | — | — | 2.56 | — | — |
| Net Debt / EBITDA | 2.19 | 2.19 | 2.03 | 0.88 | — | 0.29 | 0.76 | 1.50 |
| Debt / FCF | — | 2.84 | 1.84 | 1.07 | — | 0.35 | 1.00 | 1.55 |
| Interest Coverage | 3.24 | 3.24 | 1.09 | 6.09 | 1.42 | 20.67 | 13.10 | 11.27 |
BTMD Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
A current ratio of 1.22x means biote Corp. can comfortably meet its short-term obligations, though there is limited excess liquidity. The quick ratio of 0.79x is notably lower than the current ratio, indicating a significant portion of current assets is tied up in inventory. The current ratio has declined from 5.51x to 1.22x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.22 | 1.22 | 1.32 | 5.51 | 5.39 | 2.72 | 2.38 | 1.43 |
| Quick Ratio | 0.79 | 0.79 | 1.03 | 4.73 | 4.80 | 2.16 | 2.01 | 1.14 |
| Cash Ratio | 0.54 | 0.54 | 0.76 | 4.01 | 4.22 | 1.55 | 1.47 | 0.78 |
| Asset Turnover | — | 1.79 | 1.61 | 1.19 | 1.48 | 2.57 | 3.58 | 4.60 |
| Inventory Turnover | 2.88 | 2.88 | 3.92 | 3.34 | 4.88 | 5.08 | 10.39 | 11.12 |
| Days Sales Outstanding | — | 13.04 | 14.26 | 16.10 | 15.37 | 13.70 | 14.78 | 13.33 |
BTMD Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
biote Corp. returns 5.5% to shareholders annually — split between a 2.1% dividend yield and 3.4% buyback yield. The payout ratio of 6.4% is conservative, leaving significant room for dividend growth or reinvestment. The earnings yield of 32.7% (inverse of P/E) provides a useful comparison to bond yields when assessing the stock's relative attractiveness to fixed income.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Dividend Yield | 2.1% | 1.8% | 2.2% | 6.8% | 42.9% | 15.4% | — | — |
| Payout Ratio | 6.4% | 6.4% | 150.3% | 262.2% | — | 35.0% | 45.7% | 266.0% |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 32.7% | 28.5% | 1.5% | 2.6% | 4.3% | — | — | — |
| FCF Yield | 30.3% | 31.7% | 18.3% | 19.0% | — | 40.3% | — | — |
| Buyback Yield | 3.4% | 3.5% | 2.6% | 0.0% | 1.4% | 0.0% | — | — |
| Total Shareholder Yield | 5.5% | 5.3% | 4.9% | 6.8% | 44.3% | 15.4% | — | — |
| Shares Outstanding | — | $37M | $34M | $26M | $8M | $8M | $8M | $8M |
Peer Comparison
Compare BTMD with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 BTMDYou | $100M | 3.1 | 4.7 | 3.3 | 71.5% | 18.5% | — | 1129.3% | 2.8 |
 HIMS | $8B | 69.5 | 55.1 | 105.3 | 73.8% | 4.5% | 25.2% | 8.6% | 7.9 |
 EVAX | $20M | -2.6 | — | — | 100.0% | -122.7% | -100.2% | -294.3% | — |
 AMWL | $141M | -1.4 | — | — | 53.3% | -42.2% | -33.9% | -95.1% | — |
 NUVB | $2B | -9.3 | — | — | 86.6% | -338.7% | -53.2% | -54.3% | — |
 GDRX | $922M | 31.2 | 4.2 | 5.6 | 92.8% | 11.0% | 4.5% | 10.6% | 0.3 |
 DOCS | $4B | 20.9 | 16.8 | — | 89.1% | 33.3% | 19.3% | 19.8% | 0.0 |
 ABBV | $383B | 91.4 | 15.8 | 21.5 | 70.2% | 32.8% | 6214.7% | 23.9% | 2.4 |
 AVDL | $2B | -42.4 | — | — | 91.0% | -25.1% | -60.4% | -76.3% | — |
 TLRY | $551M | -0.1 | — | — | 29.3% | -277.9% | -89.1% | -66.2% | — |
 CLOV | $3B | -29.4 | — | — | 18.5% | -4.4% | -26.3% | -34.0% | — |
| Healthcare Median | — | 22.1 | 14.2 | 18.5 | 63.9% | -4.3% | -32.6% | -11.6% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 7 years · Updated daily
Consensus-Based Analysis Tools
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare
BTMD — Frequently Asked Questions
Quick answers to the most common questions about buying BTMD stock.
What is biote Corp.'s P/E ratio?
biote Corp.'s current P/E ratio is 3.1x. The historical average is 33.0x.
What is biote Corp.'s EV/EBITDA?
biote Corp.'s current EV/EBITDA is 4.7x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 5.1x.
Is BTMD stock overvalued?
Based on historical data, biote Corp. is trading at a P/E of 3.1x. Compare with industry peers and growth rates for a complete picture.
What is biote Corp.'s dividend yield?
biote Corp.'s current dividend yield is 2.08% with a payout ratio of 6.4%.
What are biote Corp.'s profit margins?
biote Corp. has 71.5% gross margin and 18.5% operating margin. Operating margin between 10-20% is typical for established companies.
How much debt does biote Corp. have?
biote Corp.'s Debt/EBITDA ratio is 2.8x, indicating moderate leverage. A ratio between 2-4x is manageable but warrants monitoring.